Treprostinil

Base Information

• Chemical Name: Treprostinil
• CAS No.: 289480-64-4
• Molecular Formula: C23H33NaO5
• Molecular Weight: 412.4949
• Hs Code.: 2918999090
• European Community (EC) Number: 695-793-9,808-233-7
• UNII: RUM6K67ESG
• DSSTox Substance ID: DTXSID901021654
• Nikkaji Number: J430.982K
• Wikipedia: Treprostinil
• Wikidata: Q3495231
• NCI Thesaurus Code: C61983
• RXCUI: 343048
• Pharos Ligand ID: 466RVG5KZ99Y
• Metabolomics Workbench ID: 42742
• ChEMBL ID: CHEMBL1237119
• Mol file: 289480-64-4.mol

Synonyms:((1R,2R,3AS,9AS)-2-hydroxy-1-((3S)-3-hydroxyoctyl)-2,3,3A,4,9,9A-hexahydro-1H-cylopent(b)naphthalen-5-yl)oxy)acetate;Orenitram;Remodulin;trepostinil sodium;treprostinil;treprostinil diethanolamine;treprostinil diolamin;treprostinil diolamine;treprostinil sodium;UT-15;UT-15C

Chemical Property of Treprostinil

Chemical Property:

• Vapor Pressure: 1.25E-14mmHg at 25°C
• Boiling Point: 587.1°C at 760 mmHg
• Flash Point: 199.3°C
• PSA: 86.99000
• LogP: 3.58320
• Storage Temp.: Inert atmosphere,Store in freezer, under -20°C
• XLogP3: 4.5
• Hydrogen Bond Donor Count: 3
• Hydrogen Bond Acceptor Count: 5
• Rotatable Bond Count: 10
• Exact Mass: 390.24062418
• Heavy Atom Count: 28
• Complexity: 495

Purity/Quality:

99% ^*data from raw suppliers

Treprostinilsodium >98% ^*data from reagent suppliers

Safty Information:

• Pictogram(s):  
• Hazard Codes: 

MSDS Files:

SDS file from LookChem

Useful:

• Canonical SMILES: CCCCCC(CCC1C(CC2C1CC3=C(C2)C(=CC=C3)OCC(=O)O)O)O
• Isomeric SMILES: CCCCC[C@@H](CC[C@H]1[C@@H](C[C@H]2[C@@H]1CC3=C(C2)C(=CC=C3)OCC(=O)O)O)O
• Recent ClinicalTrials: Safety and Efficacy of Treprostinil in Ischemia and Reperfusion Injury in Adult Orthotopic Liver Transplantation
• Recent EU Clinical Trials: A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects with Idiopathic Pulmonary Fibrosis (TETON-2)
• Recent NIPH Clinical Trials: MD-711 Phase 2/3 Study in PAH
• Description: Treprostinil sodium is a tricyclic benzindene prostacyclin analog that is formulated as a controlled-release tablet that uses osmotic technology.
• Uses: Remodulin? (treprostinil sodium) Injection is a sterile sodium salt formulated for subcutaneous or intravenous administration. Among PAH patients who remain symptomatic on bosentan or sildenafil, inhaled treprostinil improves exercise capacity and quality of life and is safe and well-tolerated.
• Mechanism of Action: Treprostinil sodium is a tricyclic benzindene prostacyclin analog that is formulated as a controlled-release tablet that uses osmotic technology. Plasma protein binding is 96% and bioavailability is 17%. However, oral treprostinil may be given with a meal containing as few as 250 calories and 30% fat without significantly affecting the overall bioavailability. Treprostinil is metabolized by the liver, primarily by the cytochrome P-450 (CYP) 2C8 isoenzyme and to a lesser extent by CYP 2C9. Consequently, dose adjustments are necessary for patients with Child–Pugh class A liver dysfunction whereas more advanced liver disease (class B and C) precludes use. In addition, concurrent use of a CYP2C8 inhibitor, such as gemfibrozil, results in the need for a lower dose of oral treprostinil.
• Stability: The stability of treprostinil sodium after dilution in three common i.v. infusion vehicles was assessed. Treprostinil sodium 0.13 mg/mL solution in sterile water for injection, 0.9% sodium chloride for injection, and 5% dextrose for injection appeared to be stable after storage in controlled ambulatory drug-delivery systems for 48 hours at 40 degrees C and 75% relative humidity. Treprostinil sodium 0.004 mg/mL in sterile water and 0.9% sodium chloride for injection and 0.02 mg/mL in 5% dextrose injection was also stable under the same conditions. None of the solutions showed signs of microbial growth.